Blue Water Biotech, Inc. Appoints Dr. Neil J. Campbell as President
October 10, 2023 at 09:00 am
Share
Blue Water Biotech, Inc. announced the appointments of Dr. Neil J. Campbell as President, effective immediately. Dr. Campbell has also joined the Company's board of directors. Dr. Campbell has more than 35 years of experience with public and private companies focused on biopharmaceuticals,
health technologies, nanotechnologies, artificial intelligence and super-computing. He has held leadership positions with IGEN International, now Roche; Celera Genomics; and Abbott Laboratories. In addition, he has worked as a venture capital partner and private equity advisor. He currently serves as chairman of Mosaigen(R), a commercial development company, and Patriax Industries(TM), a protective device company. Prior to joining Blue Water Biotech, Dr. Campbell was president, CEO and a director of Marizyme Inc. He also founded and served as chairman and CEO of Celios(R), a respiratory device company that was acquired by a private investment group. Prior to this, Dr. Campbell was the co-founder, president and CEO of Helomics, a personalized healthcare company focused on next-generation oncology and immune therapeutics and diagnostics. This company was acquired by a private equity investor. Dr. Campbell also held senior executive positions with SuperNova Diagnostics, EntreMed Pharmaceuticals and Life Technologies.Dr. Campbell has been a faculty member at Johns Hopkins University and Medical Institutes, Hong Kong University of Science and Tech, University of Liverpool, University of Baltimore and Duquesne University. He earned a bachelor of science degree from Norwich University, a master's degree and MBA from Webster University, and a doctorate from the University of Liverpool.
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patientâs regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
ONCONETIX, INC. 
